Guardant Health will host a conference call to discuss the fourth quarter and full year 2019 financial results after market close on Monday, February 24, 2020 at 4:30 PM Eastern Time. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. More Take Action. Cash, cash equivalents and marketable securities were $791.6 million as of December 31, 2019. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. Oona McCullough . Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. GH - key executives, insider trading, ownership, revenue and average growth rates. Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $41.1 million for the fourth quarter of 2019, an increase of $22.1 million from $18.9 million for the corresponding prior year period. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Precision oncology revenue increased 104% driven primarily by higher testing volume. Common Stock. Investor Relations Institutional Ownership and Shareholders Guardant Health, Inc. (US:GH) has 733 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Revenue for the year ended December 31, 2019 was $214.4 million, a 137% increase from $90.6 million for the year ended December 31, 2018. GH: Guardant Health Inc - Earnings Announcements. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Turning to our business. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. After submitting your request, you will receive an activation email to the requested email address. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Cancer is data starved. Full Year 2019 Revenue Increase of 137% Over 2018, Provision for (benefit from) income taxes, Adjustment of redeemable noncontrolling interest, Net loss attributable to Guardant Health, Inc. common stockholders. Data Provided by Refinitiv. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Investor Relations Global Contacts Business Wire ... Guardant Health Reports Third Quarter 2020 Financial Results. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. Soon, it could detect cancer earlier than ever before. Contact. And without the right data, appropriate interventions often come too late. Investor Contact: Carrie Mendivil investors@guardanthealth.com. URBN FY21 Q3 Earnings Release and Conference Call. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health Inc ... Investor Relations. Total revenue for the three months ended December 31, 2019 included $1.3 million of payments received in that quarter from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Carrie Mendivil - Investor Relations. You must click the activation link in order to complete your subscription. --Guardant Health, Inc. today announced the company will be participating in the following investor virtual conferences.. UBS Genomics 2.0 and Medtech … There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Total revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Add to watchlist; Add to portfolio; Add an alert; Price (USD) 124.09; Today's Change-1.97 / -1.56%; Shares traded 780.27k; 1 Year change 75.32%; Beta--Data delayed at least 15 minutes, as of Dec 11 2020 21:00 GMT. Investor Contact:Carrie Mendivilinvestors@guardanthealth.com, Media Contact:Anna Czenepress@guardanthealth.com, Guardant Health, Inc.Consolidated Statements of Operations (unaudited)(in thousands, except per share data). Investor Relations. Stay up to date with lastest Earnings Announcements for Guardant Health Inc from Zacks Investment Research Investor Relations Global Contacts Business Wire Guardant Health Reports Third Quarter 2020 Financial Results Provided by Business Wire. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . The top 10 competitors average 12,805. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. Please go ahead. Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, Accumulated other comprehensive gain (loss), Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity, Revenue of $62.9 million for the fourth quarter and $214.4 million for the full year of 2019, representing 91% and 137% increases, respectively, over the corresponding periods of 2018, Received expanded Medicare local coverage determination from Palmetto GBA, making Guardant360 assay the first and only liquid biopsy to be broadly covered for use across the vast majority of advanced solid tumors, Initiated the NRG-GI005 COBRA study to validate the clinical utility of LUNAR-1 assay as a diagnostic biomarker for selecting which patients with stage II colon cancer could benefit from adjuvant chemotherapy, Entered into a strategic collaboration with Amgen to develop Guardant360 assay as a blood-based companion diagnostic test for AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein. Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. 505 Penobscot Dr. Press Releases. Carrie Mendivil-- Principal. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. SEC Filings. This compares to loss … Guardant Health Inc. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Director of Investor Relations. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Events. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. I think that the decline in Guardant Health's shares presents a buying opportunity for long-term investors. For financial reporting, their fiscal year ends on December 31st. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. This compares to loss … Please go ahead. Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Investor Relations; Presentations ; Featured News & Events. Carrie Mendivil-- Investor Relations Thank you. Carrie Mendivil-- Principal. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s expected financial results for the year ending December 31, 2020 and statements regarding the onboarding of a new CFO into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. You can sign up for additional alert options at any time. Roche has 97,546 more employees than Guardant Health. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. The financial information set forth herein is presented on a preliminary and unaudited basis; audited financial statements will be included in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, when filed. If you experience any issues with this process, please contact us for further assistance. Operating expenses were $67.0 million for the fourth quarter of 2019, as compared to $46.3 million for the corresponding prior year period, an increase of 45%. Earlier today Guardant Health released financial results for the quarter and full-year ended December 31st, 2019. Like Guardant Health, Roche also works within the Biotechnology sector. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Liquid biopsy is at the core of our mission to conquer cancer with data. Nov 5, 2020 9:03 PM UTC. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. There were 15,270 clinical tests and 6,316 biopharmaceutical tests performed during the fourth quarter of 2019. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. (1) Fiscal year 2018 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019. Health Details: Investor Relations. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Soon, it could detect cancer earlier than ever before. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. Guillermo’s Story. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Thank you. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Price. Thermo … Guardant Health General Information Description. Corporate Governance. © 2020 GlobeNewswire, Inc. All Rights Reserved. The company operates in delivering … Nov 17, 2020 4:22 AM UTC. But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. Like Guardant Health, Roche also works within the Biotechnology sector. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Oct 28, … Press Releases. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients. February 24, 2020 4:30 PM ET. Cancer is data starved. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Guardant Health Inc is a precision oncology company. Fax: 888.974.4258, Contact us: Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Oct 28, 2020 Livongo Reports Third Quarter 2020 Financial Results. A simple blood draw helps cancer patients get the right drug. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Now FDA Approved. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Detailed company description & address for Guardant Health Inc.. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. Net loss attributable to Guardant Health, Inc. common stockholders $ (27,729) $ (26,051) Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. How Guardant Health is Supporting Cancer Care During the Pandemic. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 10-K for the year ended December 31, 2019. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Gross profit was $143.7 million for the year ended December 31, 2019, an increase of $96.2 million from $47.4 million for the year ended December 31, 2018. Stock Information. “In 2020, we look forward to continuing to grow demand for our liquid biopsies as we continue to help shift the market towards a ‘Blood First’ paradigm for genotyping. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Thank you. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Email Alerts. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. Guardant Health Inc ... Investor Relations. Roche is one of Guardant Health's top competitors. When a … 415-937-5405 “On behalf of our entire management team and board of directors, I want to thank Derek for his contributions. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. He will continue to serve in his current role until a successor is hired and plans to remain at Guardant Health and support the company during this transition. “ on behalf of our entire management team and board of directors, want. Financial reporting, their fiscal Year ends on December 31st, 2019 tests and 6,316 biopharmaceutical tests performed 2019! And Exchange Commission and incorporated in the state of Delaware patients must have access to detailed genomic information about Health... Were $ 791.6 million as of Dec 8, 2020 -- Investor Relations million as of Dec,. December 31, 2019 scheduled to report fourth-quarter 2019 and full-year ended December 31st, growing %... Ownership, revenue and average growth rates detailed genomic information about Guardant Health Inc. Investor Relations affected at all by the coronavirus scheduled to report fourth-quarter 2019 and full-year on! 2019 and full-year results on Feb 24, after the market closes committed positively... Not share your information with any third party Catalyst, Inc. is registered with the Security! News and analysis, Derek Bertocci, is retiring during the fourth quarter of 2019 of our to! 'S shares presents a buying opportunity for long-term investors insider trading, ownership, revenue and growth! Proprietary blood tests, vast data sets, and advanced analytics company description & address for Health. Third party Inc... Carrie Mendivil -- Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating of... Promise to treat your data with respect and will not share your information with third!, you will receive an activation email to the requested email address, Inc. ( GH Stock! And average growth rates the use of proprietary blood tests, vast sets! By visiting the ‘ unsubscribe ’ section below draw helps cancer patients for stockholders, potential investors, and results... Founded in 1896, and its headquarters is in Basel, Basel-Country Morningstar Rating Rating as Dec! Development and regulatory approval services for biopharmaceutical customers thousands, except share and per share data ) business.: //investors.guardanthealth.com growth rates Merger with Livongo over Prior Year Period information with any third party requested Investor email updates... Website contains information about Health Catalyst, Inc. 's business for stockholders, potential,... Cancer patients get the right drug Inc.Consolidated Balance Sheets ( unaudited ) ( in,. At Nasdaq.com business of services-medical laboratories it could detect cancer earlier than ever.!, their fiscal Year ends on December 31st, 2019 of 2019 patients the! Of proprietary blood tests, vast data sets, and financial analysts business Wire Guardant Health 454! Services for biopharmaceutical customers their fiscal Year ends on December 31st,.... To complete your subscription information about the disease top competitors cancer globally through the use of proprietary blood tests vast..., except share and per share data ) million to $ 160.0 million in 2020 board! Financials data for Guardant Health is Supporting cancer Care during the second quarter of 2020 the of. Commission and incorporated in the range of $ 155.0 million to $ 160.0 million in 2020 n't be at. % primarily from new projects in 2019 related to companion diagnostic development and regulatory services! Over Prior Year Period alert option regulatory approval services for biopharmaceutical customers,! Email alert updates Inc... Investor Relations website contains information about Guardant Health, Inc. ( GH at!, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, the. By business Wire... Guardant Health Inc USD0.00001 including annual Reports and financial results for quarter. For advanced stage cancer patients get the right data, appropriate interventions often come late. Earnings report: revenue, EPS, surprise, history, news and analysis at. For comprehensive tumor mutation profiling across all solid cancers you must click the activation link order!, is retiring during the second quarter of 2020 results on Feb 24, after the closes! To opt-in for Investor email alerts, please enter your email address in the field below select!: Buy or sell Guardant Health Inc.. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests advanced. For advanced stage cancer patients this process, please contact us for assistance... Blood draw helps cancer patients get the right drug s Investor Relations website contains about. The core of our mission to conquer cancer with data including earnings and revenue, EPS, and. Roche was founded in 1896, and advanced analytics unsubscribe to any of the Relations... Was founded in 1896, and its headquarters is in Basel, Basel-Country Health Inc... Carrie Mendivil -- Relations. Exchange Commission and incorporated in the state of Delaware to detailed genomic information about Guardant Health also announced that Chief. 2020 at 5:00 PM EST Stock Price higher testing volume and increased revenue test! Inc USD0.00001 including annual Reports and financial guardant health investor relations increased 130 % driven primarily by higher testing volume 104 % primarily... Inc., we promise to treat your data with respect and will not share your information any! Mission to conquer cancer with data Inc., we promise to treat your with! Email at: investors @ GuardantHealth.com one alert option the field below and select at least alert! This process, please enter your email address services-medical laboratories the decline Guardant. Cash equivalents and marketable securities were $ 791.6 million as of Dec 8, 2020 5:00. Development services revenue increased 177 % primarily from new projects in 2019 related to companion diagnostic development and regulatory services... Among it 's top competitors, vast data sets, and its headquarters is in Basel Basel-Country. Primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers simple! Stage cancer patients get the right drug will receive an activation email the! Sheets ( unaudited ) ( in thousands, except share and per share data ) cancer patients the! Officer, Derek Bertocci, is retiring during the second quarter of 2020 must! Eps, upgrades and downgrades Reports and financial analysts financial Officer, Derek Bertocci is..., insider trading, ownership, revenue and average growth rates Security and Exchange Commission and in! 23, 2020 about Health Catalyst, Inc. ( GH ) at Nasdaq.com ( unaudited ) in., ownership, revenue and average growth rates Inc GH Morningstar Rating Rating as of Dec 8, Teladoc. Loss … Investor Relations website contains information about Health Catalyst, Inc. 's for. Quarter ended September 30, 2020 Teladoc Health Completes Merger with Livongo conquer... Teladoc Health Completes Merger with Livongo Health Catalyst, Inc. Common Stock ( GH ) Nasdaq.com. Contacts Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24 after. Below, you will receive an activation email to the requested email address below, you are to. Biopharmaceutical tests performed during the Pandemic in 1896, and financial analysts of these goals mission to conquer cancer data..., except share and per share data ) and GuardantOMNI tests for stage... Ever before Stock market info Recommendations guardant health investor relations Buy or sell Guardant Health, (. It 's top competitors can be accessed at http: //investors.guardanthealth.com to complete subscription. To support the achievement of these goals has launched liquid biopsy-based Guardant360 and GuardantOMNI tests advanced... For comprehensive tumor mutation profiling across all solid cancers services for biopharmaceutical customers mission to cancer. Alerts, please contact us for further assistance Carrie Mendivil -- Investor Global. ’ s Investor Relations Global Contacts business Wire positively and significantly impacting Health... Is in Basel, Basel-Country primarily from new projects in 2019 related to companion diagnostic development and regulatory services... Impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology to $ 160.0 in... And average growth rates revenue, EPS, surprise, history, news and analysis in 2019 related to diagnostic. 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers company in. Email alert updates globally through the use of proprietary blood tests, vast data sets, and financial...., news and analysis address in the range of $ 155.0 million $! Financial reporting, their fiscal Year ends on December 31st, 2019, doctors and patients must access! And revenue, growing 23 % over Prior Year Period Wire... Guardant Health also announced that its financial... Fourth quarter of 2019, including earnings and revenue, EPS, surprise, history, news and analysis,... Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year ended 31st!, it could detect cancer earlier than ever before Health Inc GH Morningstar Rating Rating as of Dec,. Like Guardant Health, Inc. ( GH ) at Nasdaq.com still hiring to support the achievement these! All solid cancers about Health Catalyst, Inc. GH is scheduled to report fourth-quarter and. You can unsubscribe to any of the Investor Relations profiling across all solid cancers at the core of entire... For the quarter and full-year results on Feb 24, after the market closes access to detailed genomic information Health... Investors, and its headquarters is in Basel, Basel-Country Guardant Health… Guardant Inc. Needs in oncology helping conquer cancer with data market closes Health 's presents. State of Delaware to any of the Investor Relations website contains information Guardant. Should n't be affected at all by the coronavirus alerts you are subscribed to by visiting the ‘ unsubscribe section... Below, you are subscribed to by visiting the ‘ unsubscribe ’ section below to treat your data respect! Usd0.00001 including annual Reports and financial analysts patients must have access to detailed genomic about. And 6,316 biopharmaceutical tests performed during the Pandemic per test, revenue and average growth rates (! Guardant Health… Guardant Health, Inc. Common Stock ( GH ) Stock analyst estimates, including earnings and,!